The antibody–drug conjugate landscape

Patrick Flynn,Smruthi Suryaprakash,Dan Grossman,Val Panier,John Wu

DOI: https://doi.org/10.1038/d41573-024-00064-w

IF: 112.288

2024-04-17

Nature Reviews Drug Discovery

Abstract:Nature Reviews Drug Discovery, Published online: 16 April 2024; doi:10.1038/d41573-024-00064-w The antibody–drug conjugate landscape

pharmacology & pharmacy,biotechnology & applied microbiology

What problem does this paper attempt to address?

Bibliometric analysis of antibody-drug conjugates

Ying XU,Jie ZHOU,Zhan ZHOU,Shu-qingΔ CHEN

DOI: https://doi.org/10.3969/j.issn.1005-1678.2016.06.03

2016-01-01

Abstract:Objective To retrieve and analyze domestic and international literatures about antibody-drug conjugates, and understand the recent progress and current situation.Methods PubMed, Web of Science and CNKI were searched to collect all the literatures connected with ADCs from the beginning to January, 2016.Endnote X7 was used to sort out and summarize.The type of literature, published year, first author, research institution, published journal, cited frequency, research contents and patent situation were analyzed with bibliometric methods.Results A total of 645 literatures were included, among which 495 were foreign articles and 150 were Chinese articles.The literatures greatly increased after the 21st century.The top one nation and journal which published the most articles were America and Clinical Cancer Research, respectively.Krop IE and Younes A published the most articles.Among them, the most frequently cited paper was cited up to 686 times.Selection of the targets, site-specific drug conjugation to antibodies and cytotoxic agents were frequently involved.Conclusion ADCs, which have made breakthrough progress, are the focus in the field of cancer research.However, there is still room for improvement, and we still need further exploration.
Antibody Conjugates-Recent Advances and Future Innovations

Donmienne Leung,Jacqueline M. Wurst,Tao Liu,Ruben M. Martinez,Amita Datta-Mannan,Yiqing Feng

DOI: https://doi.org/10.3390/antib9010002

2020-01-01

Antibodies

Abstract:Monoclonal antibodies have evolved from research tools to powerful therapeutics in the past 30 years. Clinical success rates of antibodies have exceeded expectations, resulting in heavy investment in biologics discovery and development in addition to traditional small molecules across the industry. However, protein therapeutics cannot drug targets intracellularly and are limited to soluble and cell-surface antigens. Tremendous strides have been made in antibody discovery, protein engineering, formulation, and delivery devices. These advances continue to push the boundaries of biologics to enable antibody conjugates to take advantage of the target specificity and long half-life from an antibody, while delivering highly potent small molecule drugs. While the "magic bullet" concept produced the first wave of antibody conjugates, these entities were met with limited clinical success. This review summarizes the advances and challenges in the field to date with emphasis on antibody conjugation, linker-payload chemistry, novel payload classes, absorption, distribution, metabolism, and excretion (ADME), and product developability. We discuss lessons learned in the development of oncology antibody conjugates and look towards future innovations enabling other therapeutic indications.
Emerging formats for next-generation antibody drug conjugates

Mahendra P Deonarain,Gokhan Yahioglu,Ioanna Stamati,Jared Marklew

DOI: https://doi.org/10.1517/17460441.2015.1025049

Abstract:Introduction: Antibody drug conjugates now make up a significant fraction of biopharma's oncology pipeline due to great advances in the understanding of the three key components and how they should be optimised together. With this clinical success comes innovation to produce new enabling technologies that can deliver more effective antibody-drug conjugates (ADCs) with a larger therapeutic index. Areas covered: There are many reviews that discuss the various strategies for ADCs design but the last 5 years or so have witnessed the emergence of a number of different antibody formats compete with the standard whole immunoglobulin. Using published research, patent applications and conference disclosures, the authors review the many antibody and antibody-like formats, discussing innovations in protein engineering and how these new formats impact on the conjugation strategy and ultimately the performance. The alternative chemistries that are now available offer new linkages, stability profiles, drug:antibody ratio, pharmacokinetics and efficacy. The different sizes being considered promise to address issues, such as tumour penetration, circulatory half-life and side-effects. Expert opinion: ADCs are at the beginning of the next stage in their evolution and as these newer formats are developed and examined in the clinic, we will discover if the predicted features have a clinical benefit. From the commercial activity, it is envisaged that smaller or fragment-based ADCs will expand oncological applications.
New Horizons in Therapeutic Antibody Discovery: Opportunities and Challenges versus Small-Molecule Therapeutics

Alison J. Smith

DOI: https://doi.org/10.1177/1087057114562544

IF: 3.341

2015-04-01

SLAS DISCOVERY

Abstract:Antibody drugs have become an increasingly significant component of the therapeutic landscape. Their success has been driven by some of their unique properties, in particular their very high specificity and selectivity, in contrast to the off-target liabilities of small molecules (SMs). Antibodies can bring additional functionality to the table with their ability to interact with the immune system, and this can be further manipulated with advances in antibody engineering. This review summarizes what antibody therapeutics have achieved to date and what opportunities and challenges lie ahead. The target landscape for large molecules (LMs) versus SMs and some of the challenges for antibody drug development are discussed. Effective penetration of membrane barriers and intracellular targeting is one challenge, particularly across the highly resistant blood-brain barrier. The expanding pipeline of antibody-drug conjugates offers the potential to combine SM and LM modalities in a variety of creative ways, and antibodies also offer exciting potential to build bi- and multispecific molecules. The ability to pursue more challenging targets can also be further exploited but highlights the need for earlier screening in functional cell-based assays. I discuss how this might be addressed given the practical constraints imposed by high-throughput screening sample type and process differences in antibody primary screening.

biochemical research methods,biotechnology & applied microbiology,chemistry, analytical
How antibody–drug conjugates aim to take down cancer

Benjamin Plackett

DOI: https://doi.org/10.1038/d41586-024-01426-5

IF: 64.8

2024-05-30

Nature

Abstract:Scientists are trying to work out how to balance potency with toxicity and tackle the cost of next-generation therapeutics. Scientists are trying to work out how to balance potency with toxicity and tackle the cost of next-generation therapeutics.

multidisciplinary sciences
Antibody Drug Conjugates in Urological Cancers: A Review of the Current Landscape

Aruni Ghose,Patricia Lapitan,Vedika Apte,Adheesh Ghosh,Abhinav Kandala,Sreejana Basu,Jo Parkes,Sayali D. Shinde,Stergios Boussios,Anand Sharma,Prantik Das,Nikhil Vasdev,Sara E. Rebuzzi,Yüksel Ürün,Ravindran Kanesvaran,Akash Maniam,Giuseppe L. Banna

DOI: https://doi.org/10.1007/s11912-024-01524-7

2024-04-25

Current Oncology Reports

Abstract:Our review delves into the progress across urological malignancies and discusses ongoing challenges and future directions in antibody–drug conjugate (ADC) development, emphasising their transformative potential in cancer care.

oncology
Recent Technological and Intellectual Property Trends in Antibody–Drug Conjugate Research

Youngbo Choi,Youbeen Choi,Surin Hong

DOI: https://doi.org/10.3390/pharmaceutics16020221

IF: 6.525

2024-02-04

Pharmaceutics

Abstract:Antibody–drug conjugate (ADC) therapy, an advanced therapeutic technology comprising antibodies, chemical linkers, and cytotoxic payloads, addresses the limitations of traditional chemotherapy. This study explores key elements of ADC therapy, focusing on antibody development, linker design, and cytotoxic payload delivery. The global rise in cancer incidence has driven increased investment in anticancer agents, resulting in significant growth in the ADC therapy market. Over the past two decades, notable progress has been made, with approvals for 14 ADC treatments targeting various cancers by 2022. Diverse ADC therapies for hematologic malignancies and solid tumors have emerged, with numerous candidates currently undergoing clinical trials. Recent years have seen a noteworthy increase in ADC therapy clinical trials, marked by the initiation of numerous new therapies in 2022. Research and development, coupled with patent applications, have intensified, notably from major companies like Pfizer Inc. (New York, NY, USA), AbbVie Pharmaceuticals Inc. (USA), Regeneron Pharmaceuticals Inc. (Tarrytown, NY, USA), and Seagen Inc. (Bothell, WA, USA). While ADC therapy holds great promise in anticancer treatment, challenges persist, including premature payload release and immune-related side effects. Ongoing research and innovation are crucial for advancing ADC therapy. Future developments may include novel conjugation methods, stable linker designs, efficient payload delivery technologies, and integration with nanotechnology, driving the evolution of ADC therapy in anticancer treatment.

pharmacology & pharmacy
Antibody-drug Conjugates: Design and Clinical Progress

Yu-jie Wang,Xin Cao,Xiao-yu Liu,Xiao-ling Lu,Yu-yan Li,Bing-hua Jiao

DOI: https://doi.org/10.16438/j.0513-4870.2016-0139

2016-01-01

Abstract:Antibody-drug conjugates, constructed with monoclonal antibodies, linker and cytotoxins, have distinctive advantages over chemotherapy drugs and antibody drugs in cancer therapy. In this review, the strategy of developing ADCs, and the important progress in past decade are well summarized. The representative ADCs in the pipeline are introduced and characterized with their new features. While, perspective for future directions of ADCs is proposed.
Antibody-Drug Conjugates: Advancing from magic bullet to biological missile

Ana Carolina. Veneziani,Suku Sneha,Amit M. Oza

DOI: https://doi.org/10.1158/1078-0432.ccr-23-3414

IF: 13.801

2024-02-03

Clinical Cancer Research

Abstract:Precision drug development is focusing on targeting tumor cell surface proteins for therapeutic delivery, maximizing biomarker identified on-target damage to the tumor while minimizing toxicity. A recent article demonstrated high expression of B7-H4 antigen on resistant ovarian cancer cells and described preclinical activity of B7-H4-directed antibody-drug conjugate.

oncology
Antibody-drug conjugates: Principles and opportunities

Zhi Xin Phuna,Prashanth Ashok Kumar,Elio Haroun,Dibyendu Dutta,Seah H. Lim

DOI: https://doi.org/10.1016/j.lfs.2024.122676

IF: 6.78

2024-05-01

Life Sciences

Abstract:Antibody–drug conjugates (ADCs) are immunoconjugates that combine the specificity of monoclonal antibodies with a cytotoxic agent. The most appealing aspects of ADCs include their potential additive or synergistic effects of the innate backbone antibody and cytotoxic effects of the payload on tumors without the severe toxic side effects often associated with traditional chemotherapy. Recent advances in identifying new targets with tumor-specific expression, along with improved bioactive payloads and novel linkers, have significantly expanded the scope and optimism for ADCs in cancer therapeutics. In this paper, we will first provide a brief overview of antibody specificity and the structure of ADCs. Next, we will discuss the mechanisms of action and the development of resistance to ADCs. Finally, we will explore opportunities for enhancing ADC efficacy, overcoming drug resistance, and offer future perspectives on leveraging ADCs to improve the outcome of ADC therapy for cancer treatment.

pharmacology & pharmacy,medicine, research & experimental
Antibody-Drug Conjugates: Design, Formulation and Physicochemical Stability

Satish K. Singh,Donna L. Luisi,Roger H. Pak

DOI: https://doi.org/10.1007/s11095-015-1704-4

IF: 4.58

2015-05-19

Pharmaceutical Research

Abstract:The convergence of advanced understanding of biology with chemistry has led to a resurgence in the development of antibody-drug conjugates (ADCs), especially with two recent product approvals. Design and development of ADCs requires the synergistic combination of the monoclonal antibody, the linker and the payload. Advances in antibody science has enabled identification and generation of high affinity, highly selective, humanized or human antibodies for a given target. Novel linker technologies have been synthesized and highly potent cytotoxic drug payloads have been created. As the first generation of ADCs utilizing lysine and cysteine chemistries moves through the clinic and into commercialization, second generation ADCs involving site specific conjugation technologies are being evaluated and tested. The latter aim to be better characterized and controlled, with wider therapeutic indices as well as improved pharmacokinetic-pharmacodynamic (PK-PD) profiles. ADCs offer some interesting physicochemical properties, due to conjugation itself, and to the (often) hydrophobic payloads that must be considered during their CMC development. New analytical methodologies are required for the ADCs, supplementing those used for the antibody itself. Regulatory filings will be a combination of small molecule and biologics. The regulators have put forth some broad principles but this landscape is still evolving.

pharmacology & pharmacy,chemistry, multidisciplinary
Antibody-drug conjugates: recent advances in conjugation and linker chemistries

Kyoji Tsuchikama,Zhiqiang An

DOI: https://doi.org/10.1007/s13238-016-0323-0

2016-10-14

Abstract:The antibody-drug conjugate (ADC), a humanized or human monoclonal antibody conjugated with highly cytotoxic small molecules (payloads) through chemical linkers, is a novel therapeutic format and has great potential to make a paradigm shift in cancer chemotherapy. This new antibody-based molecular platform enables selective delivery of a potent cytotoxic payload to target cancer cells, resulting in improved efficacy, reduced systemic toxicity, and preferable pharmacokinetics (PK)/pharmacodynamics (PD) and biodistribution compared to traditional chemotherapy. Boosted by the successes of FDA-approved Adcetris® and Kadcyla®, this drug class has been rapidly growing along with about 60 ADCs currently in clinical trials. In this article, we briefly review molecular aspects of each component (the antibody, payload, and linker) of ADCs, and then mainly discuss traditional and new technologies of the conjugation and linker chemistries for successful construction of clinically effective ADCs. Current efforts in the conjugation and linker chemistries will provide greater insights into molecular design and strategies for clinically effective ADCs from medicinal chemistry and pharmacology standpoints. The development of site-specific conjugation methodologies for constructing homogeneous ADCs is an especially promising path to improving ADC design, which will open the way for novel cancer therapeutics.

cell biology
Exploring the next generation of antibody–drug conjugates

Kyoji Tsuchikama,Yasuaki Anami,Summer Y. Y. Ha,Chisato M. Yamazaki

DOI: https://doi.org/10.1038/s41571-023-00850-2

IF: 78.8

2024-01-09

Nature Reviews Clinical Oncology

Abstract:Antibody–drug conjugates (ADCs) are a promising cancer treatment modality that enables the selective delivery of highly cytotoxic payloads to tumours. However, realizing the full potential of this platform necessitates innovative molecular designs to tackle several clinical challenges such as drug resistance, tumour heterogeneity and treatment-related adverse effects. Several emerging ADC formats exist, including bispecific ADCs, conditionally active ADCs (also known as probody–drug conjugates), immune-stimulating ADCs, protein-degrader ADCs and dual-drug ADCs, and each offers unique capabilities for tackling these various challenges. For example, probody–drug conjugates can enhance tumour specificity, whereas bispecific ADCs and dual-drug ADCs can address resistance and heterogeneity with enhanced activity. The incorporation of immune-stimulating and protein-degrader ADCs, which have distinct mechanisms of action, into existing treatment strategies could enable multimodal cancer treatment. Despite the promising outlook, the importance of patient stratification and biomarker identification cannot be overstated for these emerging ADCs, as these factors are crucial to identify patients who are most likely to derive benefit. As we continue to deepen our understanding of tumour biology and refine ADC design, we will edge closer to developing truly effective and safe ADCs for patients with treatment-refractory cancers. In this Review, we highlight advances in each ADC component (the monoclonal antibody, payload, linker and conjugation chemistry) and provide more-detailed discussions on selected examples of emerging novel ADCs of each format, enabled by engineering of one or more of these components.

oncology
Biophysical properties of the clinical-stage antibody landscape

Tushar Jain,Tingwan Sun,Stéphanie Durand,Amy Hall,Nga Rewa Houston,Juergen H Nett,Beth Sharkey,Beata Bobrowicz,Isabelle Caffry,Yao Yu,Yuan Cao,Heather Lynaugh,Michael Brown,Hemanta Baruah,Laura T Gray,Eric M Krauland,Yingda Xu,Maximiliano Vásquez,K Dane Wittrup,Juergen H. Nett,Laura T. Gray,Eric M. Krauland,K. Dane Wittrup

DOI: https://doi.org/10.1073/pnas.1616408114

IF: 11.1

2017-01-17

Proceedings of the National Academy of Sciences

Abstract:Significance In addition to binding to a desired target molecule, all antibody drugs must also meet a set of criteria regarding the feasibility of their manufacture, stability in storage, and absence of off-target stickiness. This suite of characteristics is often termed “developability.” We present here a comprehensive analysis of these properties for essentially the full set of antibody drugs that have been tested in phase-2 or -3 clinical trials, or are approved by the FDA. Surprisingly, many of the drugs or candidates in this set exhibit properties that indicate significant developability risks; however, the number of such red warning flags decreases with advancement toward approval. This reference dataset should help prioritize future drug candidates for development.

multidisciplinary sciences
Antibody-drug conjugates: prospects for the next generation

Meriem Grairi,Marc Le Borgne

DOI: https://doi.org/10.1016/j.drudis.2024.104241

IF: 8.369

2024-11-18

Drug Discovery Today

Abstract:The concept of a 'magic bullet' was first introduced by Paul Ehrlich in the early 1900s, he foresaw the advent of targeted therapies and the specific killing of harmful cells and/or microorganisms. However, these therapies were only used in the clinic after the second half of the 20th century with the development of specific monoclonal antibodies. To date, 13 antibody-drug conjugates (ADCs) are commercially available. Many advances have been made by modifying one or several of the three main...

pharmacology & pharmacy
Antibody–Drug Conjugates: The Dynamic Evolution from Conventional to Next-Generation Constructs

Virginia Metrangolo,Lars H. Engelholm

DOI: https://doi.org/10.3390/cancers16020447

2024-01-21

Cancers

Abstract:Introduced almost two decades ago, ADCs have marked a breakthrough in the targeted therapy era, providing clinical benefits to many cancer patients. While the inherent complexity of this class of drugs has challenged their development and broad application, the experience gained from years of trials and errors and recent advances in construct design and delivery have led to an increased number of ADCs approved or in late clinical development in only five years. Target and payload diversification, along with novel conjugation and linker technologies, are at the forefront of next-generation ADC development, renewing hopes to broaden the scope of these targeted drugs to difficult-to-treat cancers and beyond. This review highlights recent trends in the ADC field, focusing on construct design and mechanism of action and their implications on ADCs' therapeutic profile. The evolution from conventional to innovative ADC formats will be illustrated, along with some of the current hurdles, including toxicity and drug resistance. Future directions to improve the design of next-generation ADCs will also be presented.

oncology
Pharmaceutical innovation and advanced biotechnology in the biotech-pharmaceutical industry for antibody-drug conjugate development

Qi Ma,Puro Durga,Frederick X.C. Wang,Hang-Ping Yao,Ming-Hai Wang

DOI: https://doi.org/10.1016/j.drudis.2024.104057

IF: 8.369

2024-06-08

Drug Discovery Today

Abstract:Antibody-drug conjugates (ADCs), from prototypes in the 1980s to first- and second-generation products in the 2000s, and now in their multiformats, have progressed tremendously to meet oncological challenges. Currently, 13 ADCs have been approved for medical practice, with over 200 candidates in clinical trials. Moreover, ADCs have evolved into different formats, including bispecific ADCs, probody-drug conjugates, pH-responsive ADCs, target-degrading ADCs, and immunostimulating ADCs....

pharmacology & pharmacy
Antibody-Drug Conjugates: The New Frontier of Chemotherapy

Sara Ponziani,Giulia Di Vittorio,Giuseppina Pitari,Anna Maria Cimini,Matteo Ardini,Roberta Gentile,Stefano Iacobelli,Gianluca Sala,Emily Capone,David J. Flavell,Rodolfo Ippoliti,Francesco Giansanti

DOI: https://doi.org/10.3390/ijms21155510

IF: 5.6

2020-07-31

International Journal of Molecular Sciences

Abstract:In recent years, antibody-drug conjugates (ADCs) have become promising antitumor agents to be used as one of the tools in personalized cancer medicine. ADCs are comprised of a drug with cytotoxic activity cross-linked to a monoclonal antibody, targeting antigens expressed at higher levels on tumor cells than on normal cells. By providing a selective targeting mechanism for cytotoxic drugs, ADCs improve the therapeutic index in clinical practice. In this review, the chemistry of ADC linker conjugation together with strategies adopted to improve antibody tolerability (by reducing antigenicity) are examined, with particular attention to ADCs approved by the regulatory agencies (the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA)) for treating cancer patients. Recent developments in engineering Immunoglobulin (Ig) genes and antibody humanization have greatly reduced some of the problems of the first generation of ADCs, beset by problems, such as random coupling of the payload and immunogenicity of the antibody. ADC development and clinical use is a fast, evolving area, and will likely prove an important modality for the treatment of cancer in the near future.

biochemistry & molecular biology,chemistry, multidisciplinary
The Journey of Antibody–Drug Conjugates: Lessons Learned from 40 Years of Development

Raffaele Colombo,Paolo Tarantino,Jamie R. Rich,Patricia M. LoRusso,Elisabeth G.E. de Vries

DOI: https://doi.org/10.1158/2159-8290.cd-24-0708

IF: 28.2

2024-10-24

Cancer Discovery

Abstract:Antibody–drug conjugates (ADC) represent one of the most rapidly expanding treatment modalities in oncology, with 11 ADCs approved by the FDA and more than 210 currently being tested in clinical trials. Spanning over 40 years, ADC clinical development has enhanced our understanding of the multifaceted mechanisms of action for this class of therapeutics. In this article, we discuss key insights into the toxicity, efficacy, stability, distribution, and fate of ADCs. Furthermore, we highlight ongoing challenges related to their clinical optimization, the development of rational sequencing strategies, and the identification of predictive biomarkers. Significance: The development and utilization of ADCs have allowed for relevant improvements in the prognosis of multiple cancer types. Concomitantly, the rise of ADCs in oncology has produced several challenges, including the prediction of their activity, their utilization in sequence, and minimization of their side effects, that still too often resemble those of the cytotoxic molecule that they carry. In this review, we retrace 40 years of development in the field of ADCs and delve deep into the mechanisms of action of these complex therapeutics and reasons behind the many achievements and failures observed in the field to date.

oncology
Strategies and challenges for the next generation of antibody–drug conjugates

Alain Beck,Liliane Goetsch,Charles Dumontet,Nathalie Corvaïa

DOI: https://doi.org/10.1038/nrd.2016.268

IF: 112.288

2017-03-17

Nature Reviews Drug Discovery

Abstract:Key PointsThe development of antibody–drug conjugates (ADCs) has benefited from general improvements in the design of therapeutic monoclonal antibodies (mAbs) and from specific improvements in regard to methods for conjugate synthesis through which both homogeneity and stability is enhanced.Diversification of linking strategies and payloads has opened new perspectives to improve drug delivery to tumours while reducing drug exposure to normal tissues. To enhance the therapeutic index of ADCs, either the potency of the cytotoxic agent has to be improved to lower the minimum effective dose or the tumour selectivity has to be improved to increase the maximum tolerated dose.Protein structural characterization tools such as mass spectrometry and the development of quantitative bioanalytical assays will contribute to the identification of early-developability criteria for all of the ADC components (antibody, drug and linker).Recent ADC development has created a renewed interest in natural cytotoxic products, which are typically highly potent cytotoxic agents but often have unacceptable toxicities. In the future, breakthroughs in the efficacy of ADCs are likely to involve conjugates with previously unknown mechanisms of action.Alternative formats to mAbs, such as protein scaffolds (designed ankyrin-repeat proteins (DARPins), nanobodies, single-chain variable fragments (scFvs) and peptide–drug conjugates), dual-labelled ADCs and biparatopic drug conjugates, present new research avenues.There are several possible indications for ADCs: as single agents in patients with refractory or relapsing disease; in palliative settings, for consolidation or maintenance; and in combination with other agents as first-line therapy or in relapsed patients.

pharmacology & pharmacy,biotechnology & applied microbiology

The antibody–drug conjugate landscape

Bibliometric analysis of antibody-drug conjugates

Antibody Conjugates-Recent Advances and Future Innovations

Emerging formats for next-generation antibody drug conjugates

New Horizons in Therapeutic Antibody Discovery: Opportunities and Challenges versus Small-Molecule Therapeutics

How antibody–drug conjugates aim to take down cancer

Antibody Drug Conjugates in Urological Cancers: A Review of the Current Landscape

Recent Technological and Intellectual Property Trends in Antibody–Drug Conjugate Research

Antibody-drug Conjugates: Design and Clinical Progress

Antibody-Drug Conjugates: Advancing from magic bullet to biological missile

Antibody-drug conjugates: Principles and opportunities

Antibody-Drug Conjugates: Design, Formulation and Physicochemical Stability

Antibody-drug conjugates: recent advances in conjugation and linker chemistries

Exploring the next generation of antibody–drug conjugates

Biophysical properties of the clinical-stage antibody landscape

Antibody-drug conjugates: prospects for the next generation

Antibody–Drug Conjugates: The Dynamic Evolution from Conventional to Next-Generation Constructs

Pharmaceutical innovation and advanced biotechnology in the biotech-pharmaceutical industry for antibody-drug conjugate development

Antibody-Drug Conjugates: The New Frontier of Chemotherapy

The Journey of Antibody–Drug Conjugates: Lessons Learned from 40 Years of Development

Strategies and challenges for the next generation of antibody–drug conjugates